LETTER

The contribution of common regulatory and protein-coding *TYR* variants in the genetic architecture of albinism

Vincent Michaud[1,2], Eulalie Lasseaux[1], David J. Green[3], Dave T. Gerrard,[3] Claudio Plaisant[1], UK Biobank Eye and Vision Consortium, Tomas Fitzgerald[4], Ewan Birney[4], Benoît Arveiler[1,2], Graeme C. Black[3,5], Panagiotis I. Sergouniotis[3,5,6]

[1] Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.

[2] INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

[3] Division of Evolution, Infection & Genomics, School of Biological Sciences, Faculty of Biology, Medicines and Health, University of Manchester, Manchester, UK.

[4] European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Cambridge, UK.

[5] Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

[6] Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

These authors contributed equally: VM, EL, DJG

These authors contributed equally: BA, GCB

Corresponding authors: BA, GCB, PIS.

ABSTRACT

Genetic diseases have been historically segregated into rare Mendelian and common complex conditions.[1,2] Large-scale studies using genome sequencing are eroding this distinction and are gradually unmasking the underlying complexity of human traits.[3–8] Aiming to gain insights into the genetic architecture of rare recessive disorders, we studied a cohort of 1,313 individuals with albinism, an archetypal Mendelian condition. We investigated the contribution of protein-coding and regulatory variants both rare and common. We focused on *TYR,* the gene encoding tyrosinase, and found that a high-frequency promoter variant, *TYR* c.-301C>T [rs4547091], modulates the penetrance of a prevalent, disease-associated missense change, *TYR* c.1205G>A [rs1126809]. We also found that homozygosity for a haplotype formed by three common, functionally-relevant variants, *TYR* c.[-301C;575C>A;1205G>A], is associated with a high probability of receiving an albinism diagnosis (OR>82). This genotype is also associated with reduced visual acuity and increased central retinal thickness in UK Biobank participants. Finally, we report how the combined analysis of rare and common variants increases diagnostic yield and informs genetic counselling in families with albinism.

MAIN

There is abundant evidence supporting the view that rare genetic diseases are caused by rare, high-impact variants in individual genes. However, for most known rare disorders, it is not possible to identify such pathogenic changes in every affected proband, leaving significant diagnostic and knowledge gaps.[9–11] In recent years, the emergence of comprehensive rare disease and population-based resources that link genomic and phenotypic data (e.g. UK Biobank[12], Genomics England 100,000 Genomes Project[13]) has offered unprecedented opportunities for genetic discovery. Through integrative analysis of these datasets, we can now achieve line-of-sight for uncovering complex molecular explanations in people with rare disorders who have hitherto remained undiagnosable.

Albinism, a rare condition characterised by decreased ocular pigmentation and altered visual system organisation[14], had a pivotal role in the study of human genetics tracing back to the early 20th century.[15,16] At least 20 genes are now known to be associated with this disorder and the current diagnostic yield of genetic testing in affected cohorts approaches 75%.[17–19] Most people with a molecular diagnosis of albinism carry biallelic variants in *TYR*, the gene encoding the rate-limiting enzyme of melanin biosynthesis[20]. Building on recent work[17,21], we sought to increase our understanding of the genetic complexity of this archetypal disorder.

A cohort of 1208 people with albinism underwent testing of ≤19 albinism-related genes; these individuals were not known to be related and had predominantly European ancestries (Supplementary Table 1). A further 105 probands with albinism

73 were identified in the Genomics England 100,000 Genomes Project dataset[13]. A

74 'control' cohort of 29,497 unrelated individuals that had no recorded

75 diagnosis/features of albinism was also identified in this resource (Fig.1,

76 Supplementary Table 2, Methods).

77

Figure 1. Outline of the case-control study design



A case-control analysis was performed to gain insights into the contribution of protein-coding and regulatory variation, at the common and rare ends of the allele-frequency spectrum, in albinism. The majority of participants in the 'case' cohort (1208/1313) were identified through the database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. All these probands had at least one key ocular feature of albinism, *i.e.* nystagmus or prominent foveal hypoplasia. The remaining 105/1313 cases were identified through the Genomics England 100,000 Genomes Project dataset and had a diagnosis of albinism or a phenotype deemed consistent with partial/ocular albinism. The 'control' cohort included 29,497 unrelated individuals from the Genomics England 100,000 Genomes Project dataset, none of whom had a recorded diagnosis of albinism.

Genotypes that include selected *TYR* haplotypes in homozygous state were studied. Haplotypes of interest were defined as those formed by combinations of *TYR* variants that are predicted to be functionally relevant; three variants met the pre-determined criteria set for regulatory (*TYR* c.-301C>T) and common protein-coding (*TYR* c.575C>A and c.1205G>A) variants. The associated haplotypic blocks were analysed further using logistic regression (see Methods).

100K_GP, Genomics England 100,000 Genomes Project; eQTLs, expression quantitative trait loci; MAF, minor allele frequency; CADD, Combined Annotation Dependent Depletion score; HGMD, Human Gene Mutation Database v2021.2. *TYR* variant numbering is based on the transcript with the following identifiers: NM_000372.5 and ENST00000263321.6.

To gain insights into the contribution of common variants to the genetic architecture of albinism, we studied the impact of protein-coding changes that have minor allele frequency [MAF] ≥1% and are predicted by a computational algorithm to be functionally relevant (CADD score[22] ≥20). For *TYR*, two such variants were identified: c.575C>A (p.Ser192Tyr) [rs1042602] and c.1205G>A (p.Arg402Gln) [rs1126809]. Multiple associations have been recorded for these two changes including skin/hair pigmentation (for both variants), macular thickness (for c.575C>A) and iris colour (for c.1205G>A).[23] Furthermore, each of these changes has been shown to decrease TYR enzymatic activity *in vitro.*[24,25] Importantly, there is evidence suggesting that c.1205G>A is acting as a hypomorphic variant and is causing a mild form of albinism when in compound heterozygous state with a complete loss-of-function *TYR* mutation.[26] It is also noted that the MAF of this variant in European populations is around 27% and that multiple unaffected homozygous individuals have been reported (including >2,000 people in the control subset of the Genome Aggregation Database [gnomAD] v2.1.1)[27].

To gain insights into the contribution of regulatory variants, we studied the impact of changes that alter *TYR* regulatory elements (*i.e.* the *TYR* promoter or ENCODE-listed enhancers)[28] and affect *TYR* gene expression (*i.e.* they are known *TYR* expression quantitative trait loci [e*QTL*]). One such variant was identified, c.-301C>T [rs4547091], a fetal retinal pigment epithelium (RPE) selective eQTL[29]. This change is

100 known to alter a binding site for the transcription factor *OTX2* in the *TYR* promoter,
101 and the reference allele (c.-301C) has been shown to lead to a remarkable decrease
102 in promoter activity *in vitro*[30].
103
104 Focusing on individual sequence alterations without consideration for variant
105 interactions and/or patterns of linkage disequilibrium can lead to masking of
106 complex underlying mechanisms. To overcome this pitfall, we avoided an
107 independent analysis of each of the *TYR* c.-301C>T, c.575C>A and c.1205G>A
108 changes and instead studied the haplotype blocks that they form. Eight possible
109 haplotypes [2^3] and 36 possible haplotype pairs [2^{3-1} x (2^3+1)] may be encountered.
110 We focused only on the 8 haplotype pairs that include homozygous alleles (Fig.2A)
111 for two reasons: (1) in homozygous individuals, the underlying haplotypes can be
112 unambiguously determined, even in cases where segregation/phasing data are
113 unavailable; (2) in autosomal recessive disorders like *TYR*-related albinism,
114 phenotypic abnormalities are the result of the combined effect of two alleles; by
115 analyzing only homozygous cases, the effect of a specific haplotype can be isolated
116 and estimated with greater precision.
117
118 We used Firth regression analysis[31,32] to study how *TYR* haplotypes in homozygous
119 state affect the risk of albinism (i.e. the probability of having a diagnosis of albinism).
120 This increasingly recognised logistic regression approach has been designed to
121 handle small, imbalanced datasets (which are common in studies of rare conditions)
122 and allows for adjustment of key covariates (which is not possible in contingency
123 table methods) (Fig.1, Methods). The results are shown in Fig.2B and

124 Supplementary Table 3. This analysis identified a number of pertinent points that

125 are discussed below.

126

Figure 2. Common *TYR* variants form haplotypes that affect risk of albinism and visual performance.



a. The *TYR* haplotypes that were studied are shown. The reference allele of the *TYR* c.-301C>T [rs4547091] promoter variant reduces gene expression and is shown as C (↓); the non-reference allele increases gene expression and is shown as T (↑). The reference alleles of the c.575C>A (p.Ser192Tyr) [rs1042602] and the c.1205G>A (p.Arg402Gln) [rs1126809] missense variants are highlighted in green font while the non-reference alleles are highlighted in red font. As no homozygotes for the *TYR* [-301T;575A;1205A] and [-301T;575A;1205G] haplotypes were detected, these combinations are highlighted in grey font.

b. Risk of albinism (i.e. probability of receiving a diagnosis of albinism) in people carrying selected *TYR* haplotypes in homozygous state. Odds ratio >1 suggests an increased risk while odds ratio <1 suggests a decreased risk. Further information including numeric data can be found in Supplementary Table 3.

c. Visual acuity in UK Biobank participants carrying selected *TYR* haplotypes in homozygous state. Vision near 0.0 LogMAR is considered normal while vision >0.5 LogMAR is considered moderate/severe visual impairment. The Kruskal-Wallis p-value was 8×10^{-11}. Further information including numeric data can be found in Supplementary Table 5.

127 We found that the penetrance of the hypomorphic *TYR* c.1205G>A variant[26] is
128 modulated by the *TYR* c.-301C>T promoter change. When c.1205G>A is
129 encountered in a homozygous state and in combination with the c.-301C allele of
130 the promoter variant (which reduces *TYR* expression), the risk of albinism is high
131 (OR>24; see [C;A;A] and [C;C;A] in Fig.2B). In contrast, homozygosity for
132 c.1205G>A combined with the c.-301T allele (which increases *TYR* expression) has
133 a protective effect (OR<0.7; see [T;C;A] in Fig.2B). This observation is in keeping
134 with previous studies suggesting that penetrance can be modified by the joint
135 functional effects of regulatory and protein-coding variants.[33] We here provide a key
136 illustration of this mechanism in the context of a recessively-acting hypomorphic
137 variant.
138
139 Alongside this, we found that homozygosity for the *TYR* c.-301C>T promoter variant
140 protects against albinism (OR 0.3-0.7; see [T;C;A] and [T;C;G] in Fig.2B). Notably,
141 the allele frequency of the protective c.-301T allele, approaches 80% in people of
142 African ancestries and is around 40% in people of European ancestries[27] (see
143 Supplementary Fig.1 for the geographical distribution of the associated
144 variants/haplotypes). It can be speculated that variation in this *TYR* promoter
145 position partly accounts for the relatively low prevalence of *TYR*-related albinism in
146 people of African ancestries (Supplementary Table 4).
147
148 Our findings also highlight that homozygosity for the haplotype formed by the c.-
149 301C allele of the promoter variant (which reduces *TYR* expression) and the non-
150 reference alleles of the two common missense changes, c.575C>A and c.1205G>A,

151 is associated with a significant increase in the risk of albinism (OR >82; see [C;A;A]
152 in Fig.2B). This haplotype is present in ~1% of people with European ancestries in
153 the 1000 Genomes Project (phase 3)[34], and the associated risk of albinism is
154 comparable to that of a loss-of-function Mendelian mutation.
155
156 When the *TYR* c.[-301C;575A;1205A] and c.[-301C;575C;1205A] haplotypes
157 (corresponding to [C;A;A] and [C;C;A] in Fig.2B) were factored in as Mendelian
158 variants in a clinical-grade analysis of the case cohort, the diagnostic yield
159 increased from 57% (692/1208) to 76% (916/1208) (Figure 3). It is noted that current
160 genetic laboratory pipelines are generally suboptimally set up to identify these
161 complex high-risk haplotypes, especially when filtering is based on the rarity of
162 individual variants.
163
164

Figure 3. High level molecular diagnoses in 1208 probands from the University Hospital of Bordeaux albinism cohort.



It was not possible to detect a molecular diagnosis in 24% of cases ("unknown" category). The following genes were implicated in the remaining probands: *TYR* (34%), *OCA2* (19%), *SLC45A2* (8%), *GPR143* (5%), Hermansky-Pudlak syndrome (HPS) related genes (5%), *SLC24A5* (2%), other albinism-related genes (3%). A significant subset of cases with *TYR*-related albinism were found/presumed to carry either the *TYR* c.[-301C;575A;1205A] or the *TYR* c.[-301C;575C;1205A] haplotype (15% in heterozygous state ["*TYR* het haplotype" category]; 3% in homozygous state ["*TYR* hom haplotype" category]). Further information including a list with all molecular diagnoses can be found in Supplementary Table 1.

165 We subsequently studied the impact of the *TYR* c.[-301C;575A;1205A] haplotype
166 (corresponding to [C;A;A] in Fig.2B) in UK Biobank participants. We found that
167 people who were homozygous for this haplotype had, on average, reduced visual
168 acuity (mean LogMAR vision 0.10; Kruskal-Wallis p-value 8×10^{-11} with all pairwise
169 comparisons involving [C;A;A] being statistically significant; Fig.2C and
170 Supplementary Table 5). As visual acuity is a quantitative endophenotype of
171 albinism, this finding provides additional evidence supporting the functional
172 significance of this complex haplotype. A similar trend was noted when central
173 retinal thickness, another albinism endophenotype, was assessed (Kruskal-Wallis p-
174 value $< 2 \times 10^{-16}$; Supplementary Fig.2 and Supplementary Table 6). We expect that
175 future studies analysing visual function and ocular structure in this group of
176 homozygous individuals will provide key insights into the elusive link between RPE
177 melanin synthesis and visual system organisation.[35] Furthermore, we anticipate that
178 the study of cellular models specific to these homozygous cases (e.g. human
179 induced pluripotent stem cell-derived RPE) will advance our understanding of the
180 molecular pathology of albinism.
181
182 Lastly, we quantified the risk of albinism associated with combinations of rare and
183 common variants. For each study participant, we estimated two key contributors to
184 an individual's risk. First, we counted the number of rare, presumed Mendelian
185 variants in albinism-related genes; single nucleotide variants that have MAF<1%
186 and are labelled as disease-causing (DM) in the Human Gene Mutation Database
187 (HGMD) v2021.2[36] were considered. Subsequently, we counted the number of
188 common "risk genotypes" in *TYR* (*i.e.* c.-301C, c.575A and/or c.1205A in

189 heterozygous state). We found that the presence of >4 common *TYR* risk genotypes
190 confers an increased risk of albinism even in the absence of a rare, HGMD-listed
191 variant (OR>3.6; Table 1). We also found that, when a single heterozygous HGMD-
192 listed variant co-occurs with >1 common *TYR* risk genotype, the risk of albinism is
193 increased (OR>4.2 for rare variants in any albinism-related gene, OR>1.2 for rare
194 variants in *TYR;* Table 1). These observations provide a basis for more precise
195 genetic counseling in families with albinism.
196
197 One potential limitation of this study is our inability to stringently match the albinism
198 cases with the unaffected controls, especially in terms of recent ancestry (which can
199 be correlated with skin pigmentation). Although ancestry was included as a
200 parameter in our regression model, this analysis was imperfect as it was not
201 possible to reliably assign genetic ancestry to most albinism cases. It is known that
202 inability to fully account for differences in ancestral background between cases and
203 controls can lead to false-positive association signals.[37] We used a combination of
204 orthogonal approaches to evaluate the robustness and generalisability of our
205 findings. First, we used 35 presumed neutral single-nucleotide variants to calculate
206 the genomic inflation factor lambda (λGC)[38,39]; λ_{median} was found to be 1.04, in
207 keeping with limited confounding by ancestry (Supplementary Table 7).
208 Subsequently, we performed targeted sub-analyses of the available cohorts; the
209 results of three focused case-control studies supported our key findings and
210 increased confidence in the validity of the detected associations (Supplementary
211 Figure 3 and Supplementary Tables 8-10).
212

In conclusion, we have shown that a significant proportion of albinism risk arises from genetic susceptibility linked to common variants. Furthermore, our findings suggest that rare and common protein-coding variation in *TYR* should be considered in the context of regulatory haplotypes. The concepts discussed here are highly likely to be relevant to the understanding of other rare disorders, and haplotype-based approaches are expected to narrow the diagnostic gap for significant numbers of patients. Future work will embrace more diverse populations and focus on integrating both common and rare variants (including single-nucleotide and copy-number changes) into a single genetic risk score at scale.

223 ## ONLINE METHODS

224

225 **Cohort characteristics and genotyping**

226 *University Hospital of Bordeaux albinism cohort*: Individuals with albinism were identified through the
227 database of the University Hospital of Bordeaux Molecular Genetics Laboratory, France. This is a
228 national reference laboratory that has been performing genetic testing for albinism since 2003 and
229 has been receiving samples from individuals predominantly based in France (or French-administered
230 overseas territories). Information on the dermatological and ophthalmological phenotypes was
231 available and all people included in the study had at least one of the key ocular features of albinism,
232 *i.e.* nystagmus or absence of a foveal pit (prominent foveal hypoplasia). No pre-screening based on
233 genotype was undertaken and only individuals who were not knowingly related were included.

234

235 Genetic testing, bioinformatic analyses, and clinical interpretation were performed as previously
236 described.[17,26] Briefly, most participants had gene-panel testing of 19 genes associated with albinism
237 (*TYR*, *OCA2*, *TYRP1*, *SLC45A2*, *SLC24A5*, *C10ORF11*, *GPR143*, *HPS 1* to 10, *LYST*, *SLC38A8*)
238 using IonTorrent platforms. High-resolution array-CGH (comparative genomic hybridization) was also
239 used to detect copy number variants in these 19 genes. All genetic changes of interest were
240 confirmed with an alternative method (e.g. Sanger sequencing or quantitative PCR). Clinical
241 interpretation of variants was performed using criteria consistent with the 2015 American College of
242 Medical Genetics and Genomics (ACMG) best practice guidelines[40]. Generally, variants with MAF
243 ≥1% in large publicly available datasets (e.g. gnomAD[27]) were considered unlikely to be disease-
244 causing. We note that the genetic findings in a subset of this cohort (70%; 845/1208) have been
245 partly reported in a previous publication[17] (see Supplementary Table 1 for further information).

246

247 Due to the limited number of genes screened in this cohort, it was not possible to reliably assess
248 genetic ancestry and to objectively assign individuals to ancestry groups. Attempting to mitigate this,
249 we processed available data on self-identified ethnicity that were collected through questionnaires.
250 Responses were inspected and stratification into five broad continental groups (European, African,
251 Admixed American, East Asian, South Asian) was performed.

252

253 Informed consent was obtained from all participants or their parents in the case of minors. The study
254 was approved by the relevant local ethics committee (Comité de Protection des Personnes Sud-
255 Ouest et Outre Mer III, Bordeaux, France) and all investigations were conducted in accordance with
256 the tenets of the Declaration of Helsinki.
257
258 *Genomics England 100,000 Genomes Project cohort*: Clinical and genomic data from the Genomics
259 England 100,000 Genomes Project were accessed through a secure Research Environment that is
260 available to registered users. This dataset was collected as part of a national genome sequencing
261 initiative.[41] Enrolment was coordinated by Genomics England Limited and participants were recruited
262 mainly at National Health Service (NHS) Hospitals in the UK.[13] Clinical information was recorded in
263 Human Phenotype Ontology (HPO)[42] terms and International Classification of Diseases (ICD) codes.
264 Genome sequencing was performed in DNA samples from 78,195 individuals using Illumina HiSeq X
265 systems (150 base-pair paired-end format). Reads were aligned using the iSAAC Aligner
266 v03.16.02.19 and small variants were called using Starling v2.4.7.[43] Aggregation of single-sample
267 gVCFs was performed using the Illumina software gVCF genotyper v2019.02.29;
268 normalisation/decomposition was implemented by vt version 0.57721[44]. The multi-sample VCF was
269 then split into 1,371 roughly equal chunks to allow faster processing and the loci of interest were
270 queried using bcftools v1.9[45] (see https://research-help.genomicsengland.co.uk/display/GERE/ for
271 further information). Only variants that passed all provided site quality control criteria were
272 processed. In addition, we filtered out genotypes with: genotype score <20; read depth <10; allele
273 balance <0.2 and >0.8 for heterozygotes; allele balance >0.1 or <0.9 for homozygotes (reference and
274 alternate, respectively). Genomic annotation was performed using Ensembl VEP[46]; one additional
275 annotation was included - presence of a variant in HGMD v2021.2[36] with a "disease-causing" (DM)
276 label.
277
278 Ancestry inference was performed in this cohort using principal component analysis. Data from the
279 1000 genomes project (phase 3) dataset[41] was used and five broad super-populations were
280 projected (European, African, Admixed American, East Asian, South Asian) (further information on
281 this can be found online at https://research-
282 help.genomicsengland.co.uk/display/GERE/Ancestry+inference).

283
284 We focused on a pre-determined subset of the Genomics England 100,000 Genomes Project
285 dataset that includes only unrelated probands (n=29,602). 105 of these individuals had a diagnosis of
286 albinism, *i.e.* the ICD-10 term "Albinism" [E70.3] and/or the HPO terms "Albinism" [HP:0001022],
287 "Partial albinism" [HP:0007443] or "Ocular albinism" [HP:0001107] were assigned. Together with the
288 University Hospital of Bordeaux cases, these 105 probands formed the 'case' cohort (for the
289 albinism risk analysis). The remaining 29,497 probands had no recorded diagnosis or phenotypic
290 features of albinism and formed the 'control' cohort. We note that in-depth ophthalmic phenotyping
291 was not routinely undertaken in Genomics England 100,000 Genomes Project participants. Thus, we
292 cannot be certain that a small number of individuals with mild/subclinical forms of albinism are not
293 included in the control cohort.
294
295
296 **Identifying functional regulatory and protein-coding variants**
297 Regulatory variants: Focusing on *TYR*, we identified changes that are likely to have an impact on
298 gene regulation by selecting variants that:
299 - are known *TYR* eQTLs.
300 - alter *TYR* cis-regulatory elements, including the promoter of the gene.
301
302 To identify eQTLs, we inspected the eQTL catalogue[47] and used data from the Genotype-Tissue
303 Expression v8 (GTEx)[48] and Eye Genotype Expression (EyeGEx)[49] projects. To identify regulatory
304 elements, we used the ENCODE 3 (ENCyclopedia Of DNA Elements phase 3) dataset; the SCREEN
305 (Search Candidate cis-Regulatory Elements by ENCODE) v10 interface was utilised to query this
306 resource for regions flagged as candidate cis-regulatory elements (see
307 https://screen.encodeproject.org/ for further information and definitions).[28] Additional putative
308 regulatory elements were identified by inspecting chromatin accessibility peaks in RPE samples in
309 DESCARTES (the Developmental Single Cell Atlas of Gene Regulation and Expression)[50] and through
310 an extensive search of the biomedical literature (e.g.[29]). All these queries were conducted in January
311 2021.
312

313 Common protein-coding variants: Focusing on *TYR*, we identified common changes that are likely to
314 have an impact on protein function by selecting variants that:

315 • have a CADD PHRED-scaled score ≥20. CADD is a widely-used integrative annotation tool built
316 from more than 60 genomic features. A PHRED-scaled score ≥10 indicates a raw score in the
317 top 10% of all possible single nucleotide variants, while a score ≥20 indicates a raw score in the
318 top 1%;[22] it is noted that a cut-off of 20 has balanced sensitivity and specificity (90% and 69%
319 respectively)[51] in the context of this non-diagnostic setting.
320 • alter protein-coding sequences - including missense changes, nonsense variants and small
321 insertions/deletions; variants with a potential role on splicing (e.g. synonymous changes and
322 variants altering splice donor/acceptor sites) were not included.
323 • have "total" MAF ≥1% in gnomAD v2.1.1[27]

324

325 Rare protein-coding variants: Focusing on 19 albinism-related genes *(TYR, OCA2, TYRP1, SLC45A2,*
326 *SLC24A5, C10ORF11, GPR143, HPS 1* to *10, LYST, SLC38A8*), we identified rare changes that are
327 likely to have an impact on protein function by selecting variants that:

328 • are labelled as disease-causing (DM) in HGMD v2021.2.
329 • are included in the following HGMD v2021.2 "mutation type" categories: missense/nonsense,
330 splicing, small deletions, small insertions or small indels; gross deletions, gross
331 insertions/duplications and complex rearrangements were not analysed.
332 • have "total" MAF <1% in gnomAD v2.1.1[27].

333

334

335 **Case-control analysis to estimate albinism risk**

336 The effect of homozygosity for selected *TYR* haplotypes (formed by one common regulatory change,
337 c.-301C>T, and two common protein-coding variants, c.575C>A and c.1205G>A variants) on
338 albinism risk (i.e. the probability of receiving a diagnosis of albinism) was estimated using data from
339 the University Hospital of Bordeaux albinism cohort and the Genomics England 100,000 Genomes
340 Project dataset. A case-control analysis of a binary trait (presence/absence of albinism) was
341 conducted assuming a recessive model. Logistic regression using Firth's bias reduction method[31,32]

342 was utilised (as implemented in "logistf" R package)[50]. The following covariates were included:
343 gender, number of rare HGMD-listed variants and ancestry (Supplementary Table 3).
344
345 Although ancestry was included as a co-variate in our logistic regression model, this analysis was
346 imperfect as it was not possible to objectively determine genetic ancestry in the University Hospital
347 of Bordeaux albinism cohort (as mentioned above, self-identified ethnicity was instead used as a
348 surrogate). Confounding by ancestry (i.e population stratification) is therefore a possibility. This can
349 arise if there are systematic differences in ancestral background between cases and controls; these
350 differences can result in significantly different allele/genotype frequencies between the compared
351 groups that may lead to spurious association signals.[52] We attempted to quantify the bias in our data
352 by calculating the genomic inflation factor lambda (λGC). λGC is conceptually simple and involves
353 using a set of random genetic markers to quantitatively estimate the structural differences between
354 the case and control populations.[38,39] The selected λGC markers have to be unlinked and should not
355 be expected to show an association with the trait under study (albinism or skin pigmentation in this
356 case). We therefore selected 35 single-nucleotide variants that (i) had a CADD PHRED-scaled score
357 <5 (*i.e.* were unlikely to be functionally relevant) and (ii) were genotyped both by the gene panels
358 used in the University Hospital of Bordeaux albinism cohort and the genome sequencing assays
359 used in Genomics England 100,000 Genomes Project participants (Supplementary Table 7).
360 Subsequently, case-control comparisons were made for each of these 35 λGC markers using Firth
361 regression analysis. The resulting test statistics were then used to calculate the median value of
362 λGC.
363
364 To further understand the impact of recent ancestry on our results, we analysed selected subsets of
365 the case and control cohorts. First, we performed sub-analysis of the Genomics England 100,000
366 Genomes Project cases (n=105) and controls (n=29,497). Then we aimed to compare groups that
367 were matched both in terms of genetic ancestry and geographical origin; thus we focused on the
368 Genomics England 100,000 Genomes Project cases (n=76) and controls (n=22,927) that have
369 European ancestries (as inferred by principal component analysis). Finally, we repeated our primary
370 analysis using individuals from both the University Hospital of Bordeaux and the Genomics England
371 100,000 Genomes Project cohorts but this time focusing only on the cases (n=1,107) and controls

372 (n=22,927) that have European ancestries. The results are shown in Supplementary Figure 3 and
373 Supplementary Tables 8-10.
374
375 **Analysis of visual acuity and foveal thickness in UK Biobank participants**
376 The effect of homozygosity for selected *TYR* haplotypes was studied in UK Biobank participants. UK
377 Biobank is a biomedical resource containing in-depth genetic and health information from >500,000
378 individuals from across the UK[12]. A subset of UK Biobank volunteers underwent enhanced
379 phenotyping including visual acuity testing (131,985 individuals) and imaging of the central retina
380 (84,748 individuals)[53]; the latter was obtained using optical coherence tomography (OCT), a non-
381 invasive imaging test that rapidly generates cross-sectional retinal scans at micrometre-resolution.[54]
382 All UK Biobank volunteers analysed as part of this study were imaged using the 3D OCT-1000 Mark
383 II device (Topcon, Japan); the relevant methodology has been previously described.[53] Notably, only
384 24 UK Biobank participants are assigned a diagnosis of albinism (data field 41270; ICD-10 term
385 "Albinism" [E70.3]) of which only 7 had visual acuity measurements and none had OCT imaging; 19
386 additional individuals had a diagnosis of albinism in their primary care record data (resource 591).
387 Given that reduced visual acuity and increased central retinal thickness (due to underdevelopment of
388 the fovea) are two key hallmark features of albinism we investigated the impact of *TYR* risk
389 haplotypes on these quantitative endophenotypes.
390
391 First, genotyping array data were used to obtain genotypes for *TYR* c.575C>A [rs1042602] and *TYR*
392 c.1205G>A [rs1126809] (data field 22418 including information from the Applied Biosystems UK
393 Biobank Axiom Array containing 825,927 markers). In contrast to these two changes, the *TYR*
394 c.-301C>T [rs4547091] variant was not directly captured by the array. However, high-quality
395 (>99.9%) imputation data on this promoter change were available (data field 22828).
396
397 Subsequently, we calculated the mean of the right and left LogMAR visual acuity for each UK
398 Biobank volunteer (data fields 5201 and 5208, "instance 0" datasets). These visual acuity
399 measurements were subsequently used to compare visual performance between groups of people
400 with different homozygous haplotype combinations. As the obtained distributions deviated from

401 normality (Fig.2C), the Kruskal-Wallis test was used. Pair-wise comparisons were performed and the
402 p-values were adjusted using the Benjamini-Hochberg method (Supplementary Table 5).
403
404 To obtain central foveal thickness measurements from UK Biobank OCT images, we calculated the
405 mean of the right and left central retinal thickness (defined as the average distance between the
406 hyperreflective bands corresponding to the RPE and the internal limiting membrane (ILM), across the
407 central 1 mm diameter circle of the ETDRS grid) for each UK Biobank volunteer).[51] The obtained
408 measurements were then subsequently used to compare central macular thickness between groups
409 of UK Biobank volunteers with different homozygous *TYR* haplotype combinations. As some of the
410 obtained distributions deviated from normality (Supplementary Fig.2), the Kruskal-Wallis test was
411 used. Pair-wise comparisons were performed and the p-values were adjusted using the Benjamini-
412 Hochberg method (Supplementary Table 6).
413

414

415 **DATA AND CODE AVAILABILITY STATEMENT**
416
417 Genomics England 100,000 Genomes Project data are available through an access
418 procedure described at https://www.genomicsengland.co.uk/about-gecip/for-
419 gecip-members/data-and-data-access. UK Biobank data are available through a
420 procedure described at http://www.ukbiobank.ac.uk/using-the-resource/. All other
421 data supporting the findings of this study are available within the article (including
422 its supplementary information files) or from the authors upon request. The scripts
423 used to analyse the datasets included in this study can be found
424 at https://github.com/davidjohngreen.

425

ACKNOWLEDGEMENTS

We acknowledge the following sources of funding: the Wellcome Trust (200990/Z/16/Z, Transforming Genetic Medicine Initiative); Christopher Green; Retina UK and Fight for Sight (GR586, RP Genome Project - UK Inherited Retinal Disease Consortium); Health Education England; UK National Institute for Health Research (NIHR) Clinical Lecturer Programme (CL-2017-06-001); the French Albinism Association (Genespoir).

This research was made possible through access to the data and findings generated by the 100,000 Genomes Project. The 100,000 Genomes Project is managed by Genomics England Limited (a wholly owned company of the Department of Health and Social Care). The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. The 100,000 Genomes Project uses data provided by patients and collected by the National Health Service as part of their care and support.

We acknowledge the contribution of the Genomics England Research Consortium to the 100,000 Genomes Project. Members of this Consortium include: John C. Ambrose, Prabhu Arumugam, Roel Bevers, Marta Bleda, Freya Boardman-Pretty, Christopher R. Boustred, Helen Brittain, Mark J. Caulfield, Georgia C. Chan, Greg Elgar, Tom Fowler, Adam Giess, Angela Hamblin, Shirley Henderson, Tim J. P. Hubbard, Rob Jackson, Louise J. Jones, Dalia Kasperaviciute, Melis Kayikci, Athanasios Kousathanas, Lea Lahnstein, Sarah E. A. Leigh, Ivonne U. S. Leong,

Javier F. Lopez, Fiona Maleady-Crowe, Meriel McEntagart, Federico Minneci, Loukas Moutsianas, Michael Mueller, Nirupa Murugaesu, Anna C. Need, Peter O'Donovan, Chris A. Odhams, Christine Patch, Mariana Buongermino Pereira, Daniel Perez-Gil, John Pullinger, Tahrima Rahim, Augusto Rendon, Tim Rogers, Kevin Savage, Kushmita Sawant, Richard H. Scott, Afshan Siddiq, Alexander Sieghart, Samuel C. Smith, Alona Sosinsky, Alexander Stuckey, Mélanie Tanguy, Ana Lisa Taylor Tavares, Ellen R. A. Thomas, Simon R. Thompson, Arianna Tucci, Matthew J. Welland, Eleanor Williams, Katarzyna Witkowska, Suzanne M. Wood

This research was conducted using the UK Biobank Resource under projects 53144, 49978 and 2112. Members of the UK Biobank Eye and Vision Consortium include: Tariq Aslam, Sarah Barman, Jenny Barrett, Paul Bishop, Catey Bunce, Roxana Carare, Usha Chakravarthy, Michelle Chan, Valentina Cipriani, Alexander Day, Parul Desai, Bal Dhillon, Andrew Dick, Cathy Egan, Sarah Ennis, Paul Foster, Marcus Fruttiger, John Gallacher, David Garway-Heath, Jane Gibson, Dan Gore, Jeremy Guggenheim, Chris Hammond, Alison Hardcastle, Simon Harding, Ruth Hogg, Pirro Hysi, Pearse A. Keane, Peng T. Khaw, Anthony Khawaja, Gerassimos Lascaratos, Andrew J. Lotery, Phil Luthert, Tom Macgillivray, Sarah Mackie, Bernadette Mcguinness, Gareth Mckay, Martin Mckibbin, Danny Mitry, Tony Moore, James Morgan, Zaynah Muthy, Eoin O'Sullivan, Chris Owen, Praveen Patel, Euan Paterson, Tunde Peto, Axel Petzold, Jugnoo Rahi, Alicja Rudnicka, Jay Self, Sobha Sivaprasad, David Steel, Irene Stratton, Nicholas Strouthidis, Cathie Sudlow, Caroline Thaung, Dhanes Thomas, Emanuele Trucco, Adnan Tufail, Veronique Vitart, Stephen Vernon, Ananth Viswanathan, Cathy Williams, Katie Williams, Jayne Woodside, Max Yates, Jennifer Yip, Yalin Zheng, Robyn Tapp, Denize Atan,

Alexander Doney, Naomi Allen, Thomas Littlejohns, Panagiotis Sergouniotis, Graeme Black.

Lastly, we acknowledge the help of Cécile Courdier at the University Hospital of Bordeaux Molecular Genetics Laboratory and of Jamie Ellingford at the University of Manchester.

483 **COMPETING INTERESTS STATEMENT**

484

485 E.B. is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to
486 Dovetail, and a non-executive director of Genomics England, a limited company
487 wholly owned by the UK Department of Health and Social Care. All other authors
488 declare no competing interests.

489

490

491 **REFERENCES**

492

493 1. Claussnitzer, M. *et al.* A brief history of human disease genetics. *Nature* **577**, 179–189 (2020).

494 2. Shendure, J., Findlay, G. M. & Snyder, M. W. Genomic Medicine–Progress, Pitfalls, and
495 Promise. *Cell* **177**, 45–57 (2019).

496 3. Niemi, M. E. K. *et al.* Common genetic variants contribute to risk of rare severe
497 neurodevelopmental disorders. *Nature* **562**, 268–271 (2018).

498 4. Tilghman, J. M. *et al.* Molecular genetic anatomy and risk profile of Hirschsprung's disease.
499 *N. Engl. J. Med.* **380**, 1421–1432 (2019).

500 5. Turro, E. *et al.* Whole-genome sequencing of patients with rare diseases in a nationalhealth
501 system. *Nature* **583**, 96 (2020).

502 6. Chung, B. H. Y., Chau, J. F. T. & Wong, G. K.-S. Rare versus common diseases: a false
503 dichotomy in precision medicine. *NPJ genomic Med.* **6**, (2021).

504 7. Khan, M. *et al.* Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands
505 through integrated genomics and transcriptomics. *Genet. Med.* **22**, 1235–1246 (2020).

506 8. Harper, A. R. *et al.* Common genetic variants and modifiable risk factors underpin
507 hypertrophic cardiomyopathy susceptibility and expressivity. *Nat. Genet. 2021 532* **53**, 135–
508 142 (2021).

509 9. Boycott, K. M. *et al.* International cooperation to enable the diagnosis of all rare genetic
510 diseases. *Am. J. Hum. Genet.* **100**, 695 (2017).

511 10. Ferreira, C. R. The burden of rare diseases. *Am. J. Med. Genet. A* **179**, 885–892 (2019).

512 11. Chakravarti, A. Magnitude of Mendelian versus complex inheritance of rare disorders. *Am. J.*
513 *Med. Genet. A* (2021). doi:10.1002/AJMG.A.62463

514 12. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*
515 **562**, 203–209 (2018).

516 13. Genomics England. The National Genomic Research Library v5.1. (2019). Available at:
517 https://doi.org/10.6084/m9.figshare.4530893.v6.

518 14. Kruijt, C. C. *et al.* The phenotypic spectrum of albinism. *Ophthalmology* **125**, 1953–1960
519 (2018).

520 15. Farabee, W. C. Notes on Negro Albinism. *Science* **17**, 75 (1903).

521 16. Garrod, A. E. The Croonian Lectures on Inborn Errors of Metabolism. *Lancet* **172**, 1–7 (1908).

522 17. Lasseaux, E. *et al.* Molecular characterization of a series of 990 index patients with albinism.
523 *Pigment Cell Melanoma Res.* **31**, 466–474 (2018).

524 18. Wang, C. *et al.* [Spectrum of pathological genetic variants among 405 Chinese pedigrees
525 affected with oculocutaneous albinism]. *Chin J Med Genet* **37**, 725–730 (2020).

526 19. Mauri, L. *et al.* Clinical evaluation and molecular screening of a large consecutive series of
527 albino patients. *J. Hum. Genet.* **62**, 277–290 (2017).

528 20. Pavan, W. J. & Sturm, R. A. The genetics of human skin and hair pigmentation. *Annu. Rev.*
529 *Genomics Hum. Genet.* **20**, 41–72 (2019).

530 21. Campbell, P. *et al.* Clinical and genetic variability in children with partial albinism. *Sci. Rep.* **9**,
531 16576 (2019).

532 22. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: Predicting the
533 deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* **47**, D886–
534 D894 (2019).

535 23. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association
536 studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005 (2019).

537 24. Chaki, M. *et al.* Molecular and functional studies of tyrosinase variants among Indian
538 oculocutaneous albinism type 1 patients. *J. Invest. Dermatol.* **131**, 260–262 (2011).

539 25. Jagirdar, K. *et al.* Molecular analysis of common polymorphisms within the human Tyrosinase
540 locus and genetic association with pigmentation traits. *Pigment Cell Melanoma Res.* **27**, 552–
541 564 (2014).

542 26. Monfermé, S. *et al.* Mild form of oculocutaneous albinism type 1: phenotypic analysis of
543 compound heterozygous patients with the R402Q variant of the TYR gene. *Br. J. Ophthalmol.*
544 **103**, 1239–1247 (2019).

545 27. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
546 141,456 humans. *Nature* **581**, 434–443 (2020).

547 28. The ENCODE Project Consortium *et al.* Expanded encyclopaedias of DNA elements in the
548 human and mouse genomes. *Nature* **583**, 699–710 (2020).

549 29. Liu, B. *et al.* Genetic analyses of human fetal retinal pigment epithelium gene expression
550 suggest ocular disease mechanisms. *Commun. Biol.* **2**, 186 (2019).

551 30. Reinisalo, M., Putula, J., Mannermaa, E., Urtti, A. & Honkakoski, P. Regulation of the human
552 tyrosinase gene in retinal pigment epithelium cells: The significance of transcription factor
553 orthodenticle homeobox 2 and its polymorphic binding site. *Mol. Vis.* **18**, 38–54 (2012).

554 31. Heinze, G. & Schemper, M. A solution to the problem of separation in logistic regression. *Stat.*
555 *Med.* **21**, 2409–2419 (2002).

556 32. Firth, D. Bias Reduction of Maximum Likelihood Estimates. *Biometrika* **80**, 27 (1993).

557 33. Castel, S. E. *et al.* Modified penetrance of coding variants by cis-regulatory variation
558 contributes to disease risk. *Nat. Genet.* **50**, 1327 (2018).

559 34. Auton, A. *et al.* A global reference for human genetic variation. *Nat. 2015 5267571* **526**, 68–74
560 (2015).

561 35. Mason, C. & Guillery, R. Conversations with Ray Guillery on albinism: linking Siamese cat
562 visual pathway connectivity to mouse retinal development. *Eur. J. Neurosci.* **49**, 913–927
563 (2019).

564 36. Stenson, P. D. *et al.* The Human Gene Mutation Database (HGMD ®): optimizing its use in a
565 clinical diagnostic or research setting. *Hum. Genet.* **139**, 1197–1207 (2020).

566 37. Freedman, M. L. *et al.* Assessing the impact of population stratification on genetic association
567 studies. *Nat. Genet. 2004 364* **36**, 388–393 (2004).

568 38. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004
569 (1999).

570 39. Dadd, T., Weale, M. E. & Lewis, C. M. A critical evaluation of genomic control methods for
571 genetic association studies. *Genet. Epidemiol.* **33**, 290–298 (2009).

572 40. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint
573 consensus recommendation of the American College of Medical Genetics and Genomics and
574 the Association for Molecular Pathology. *Genet. Med. 2015 175* **17**, 405–423 (2015).

575 41. Turnbull, C. *et al.* The 100 000 Genomes Project: bringing whole genome sequencing to the
576 NHS. *BMJ* **361**, 1687 (2018).

577 42. Köhler, S. *et al.* The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **49**, D1207–
578 D1217 (2021).

579 43. Raczy, C. *et al.* Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing
580 platforms. *Bioinformatics* **29**, 2041–2043 (2013).

581 44. Tan, A., Abecasis, G. R. & Kang, H. M. Unified representation of genetic variants.
582 *Bioinformatics* **31**, 2202–2204 (2015).

583 45. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008 (2021).

584 46. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, (2016).

585 47. Nurlan, K. *et al.* A compendium of uniformly processed human gene expression and splicing
586 quantitative trait loci. *Nat. Genet.* **53**, 1290–1299 (2021).

587 48. The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
588 human tissues. *Science* **369**, 1318–1330 (2020).

589 49. Ratnapriya, R. *et al.* Retinal transcriptome and eQTL analyses identify genes associated with
590 age-related macular degeneration. *Nat. Genet.* **51**, 606–610 (2019).

591 50. Domcke, S. *et al.* A human cell atlas of fetal chromatin accessibility. *Science* **370**, (2020).

592 51. van der Velde, K. J. *et al.* GAVIN: Gene-Aware Variant INterpretation for medical sequencing.
593 *Genome Biol.* **18**, 1–10 (2017).

594 52. Marchini, J., Cardon, L. R., Phillips, M. S. & Donnelly, P. The effects of human population
595 structure on large genetic association studies. *Nat. Genet. 2004 365* **36**, 512–517 (2004).

596 53. Chua, S. Y. L. *et al.* Cohort profile: design and methods in the eye and vision consortium of
597 UK Biobank. *BMJ Open* **9**, e025077 (2019).

598 54. Drexler, W. & Fujimoto, J. G. State-of-the-art retinal optical coherence tomography. *Prog.*
599 *Retin. Eye Res.* **27**, 45–88 (2008).

600 55. Currant, H. *et al.* Genetic variation affects morphological retinal phenotypes extracted from
601 UK Biobank optical coherence tomography images. *PLoS Genet.* **17**, e1009497 (2021).
602

603 **TABLE**

604

Table 1. Contribution of different classes of albinism-related variants to disease risk

combination of common [a] and rare [b] risk genotypes	odds ratio [c]	95% confidence interval	p-value
6 common + 0 rare	391	165 - 982	0.000016
5 common + 0 rare	7.8	3.6 - 16.5	<0.00001
4 common + 0 rare	3.4	1.9 – 6.1	0.000014
3 common + 0 rare	1.5	0.8 - 2.6	0.17
2 common + 0 rare	2.3	1.3 - 4	0.002
1 common + 0 rare	1.1	0.6 - 1.9	0.84
0 common + 0 rare	0.1	0.1 - 0.2	<0.00001
6 common + 1 rare [d]	217	26.7 - 2519	0.00001
5 common + 1 rare	302	156 - 566	<0.00001
4 common + 1 rare	38	22 - 69	<0.00001
3 common + 1 rare	8.7	4.9 - 15.6	<0.00001
2 common + 1 rare	7.5	4.2 - 13.5	<0.00001
1 common + 1 rare	6	3.2 - 11.2	<0.00001
0 common + 1 rare	2.6	1.2 - 5.3	0.016
0 common + 2 rare	163	75 - 367	<0.00001
6 common + 1 rare *TYR* [d]	120	6 - 17919	0.003
5 common + 1 rare *TYR*	178	82 - 425	<0.00001
4 common + 1 rare *TYR*	38.6	20 - 80	<0.00001
3 common + 1 rare *TYR*	5.3	2.6 – 11	<0.00001
2 common + 1 rare *TYR*	2.4	1.2 – 5.4	0.02
1 common + 1 rare *TYR* [d]	0.6	0.2 – 1.9	0.43
0 common + 1 rare *TYR* [d]	2.3	0.4 – 8	0.28
0 common + 2 rare *TYR* [d]	446	100 - 4270	<0.00001

[a] presence of each of the following *TYR* variants in heterozygous state was considered as one common risk genotype: c.-301C [rs4547091]; c.575C>A (p.Ser192Tyr) [rs1042602]; c.1205G>A (p.Arg402Gln) [rs1126809]. *TYR* variant numbering is based on the transcript with the following identifiers: NM_000372.5 and ENST00000263321.6.

[b] autosomal albinism-related genes were inspected and each heterozygous protein-coding change with a minor-allele frequency <1% and a "disease-causing" (DM) label in the Human Gene Mutation Database (HGMD) v2021.2 was considered as one rare risk genotype. Such genotypes in the *TYR* gene are labelled "*rare TYR*".

[c] Firth regression analysis with gender and ancestry as covariates was used to estimate odds ratios and p-values; 1,121 probands with albinism and 29,453 unrelated controls were included (Supplementary Table 1).

[d] Less than 10 individuals were included in the smallest subgroup of these categories, reducing the reliability of the associated findings.

605